Niraparib (Zejula™): First Global Approval – Oral maintenance therapy for recurrent ovarian-related cancer

Niraparib (Zejula™): First Global Approval –  Oral maintenance therapy for recurrent ovarian-related cancer

The recent first global approval of niraparib has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.

Continue reading “Niraparib (Zejula™): First Global Approval – Oral maintenance therapy for recurrent ovarian-related cancer”

Avelumab (Bavencio®): First Global Approval – Inaugural Immunotherapy for Metastatic Merkel Cell Carcinoma

Avelumab (Bavencio®): First Global Approval – Inaugural Immunotherapy for Metastatic Merkel Cell Carcinoma

The recent first global approval of avelumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.

Continue reading “Avelumab (Bavencio®): First Global Approval – Inaugural Immunotherapy for Metastatic Merkel Cell Carcinoma”